Mesoblast Limited files as an Australian foreign private issuer, and its SEC reports document ASX announcements for its ADR-listed securities. Form 6-K reports incorporate Appendix 4C activity reports, press releases and R&D materials covering Ryoncil commercialization, operating cash spend, clinical programs for rexlemestrocel-L and Ryoncil, FDA regulatory updates and the company’s mesenchymal lineage cell therapy platform.
The filing record also documents capital-structure and governance matters through ASX appendices for proposed and quoted securities, unquoted equity securities, cessation of securities and changes in director interests. These disclosures connect Mesoblast’s public reporting to product revenue, pipeline development, equity issuance and foreign-issuer compliance under Form 20-F reporting.
Mesoblast Limited furnished a Form 6-K to provide investors with its Australian Securities Exchange Appendix 4C quarterly report for the quarter ended September 30, 2025. The Appendix 4C is attached as Exhibit 99.1 and incorporated by reference. The filing is an administrative submission linking U.S. investors to the company’s ASX quarterly cash flow and activities report.
Mesoblast Limited Schedule 13G/A filed for ordinary shares/ADRs reports that Gregory George, his sons James and Grant George, and G to the Fourth Investments, LLC collectively hold substantial positions as of September 11, 2025. Gregory George is reported as beneficial owner of 275,851,734 shares in the aggregate (21.59% of the 1,277,782,187 outstanding shares), including 137,123,887 shares he solely owns and discretionary voting or dispositive authority over additional shares held by G to the Fourth Investments and by his sons. G to the Fourth Investments, LLC holds 126,727,847 shares (9.92%). James George and Grant George each report 6,000,000 shares (0.47% each). The filing states the holdings were not acquired to change or influence control.
Mesoblast Limited submitted a Form 6-K as a foreign private issuer for August 2025. The company furnished to U.S. investors an Australian Securities Exchange press release and an investor presentation dated August 29, 2025, attaching them as Exhibits 99.1 and 99.2 by reference.
Mesoblast is a commercial-stage biotech focused on allogeneic mesenchymal lineage cell therapies. The company received FDA approval in December 2024 for remestemcel-L (Ryoncil®) to treat steroid-refractory acute graft-versus-host disease in pediatric patients and launched the product in March 2025. Since launch through June 30, 2025, Mesoblast reported net product sales of $11.3 million.
The company reported a net loss of $102.1 million for the year ended June 30, 2025 and cumulative losses of $1,010.9 million since inception. At June 30, 2025 Mesoblast held $161.6 million in cash and reported net cash usage from operations of $50.0 million for the year. Management states current cash plus forecasted Ryoncil® revenue are sufficient to meet operating cash needs for the next 12 months, and they expect to refinance existing borrowings within that period. The company remains dependent on third-party manufacturers, certain single-source suppliers and successful commercialization, and highlights multiple operational, regulatory and market risks that could affect future results.